Sanofi and GSK announcedthis morning their COVID-19 vaccine candidate demonstrated a strong immune response in adults in a phase 2 clinical trial.
Why it matters: Sanofi and GSK say their recombinant protein-based vaccine candidate could ultimately serve as a universal COVID-19 vaccine booster, able to boost immunity regardless of the vaccination first received.
